Skip to main content
Premium Trial:

Request an Annual Quote

BD Biosciences to Open New Facility in Florida

NEW YORK (GenomeWeb News) – Becton Dickinson’s BD Biosciences division will open a new manufacturing facility in Miami-Dade County, Florida, according to a statement today from the Beacon Council, the county’s economic development organization.
 
BD will invest more than $20 million in renovating the 90,000-square-feet facility, which formerly belonged to Ivax Pharmaceuticals. The Beacon Council said that the new manufacturing facility is expected to create 75 “high-paying” jobs over the next eight years.
 
BD Biosciences will produce cell media supplements for vaccines and biopharmaceuticals at the new facility.
 
BD qualifies for performance-based incentives of $1.4 million from state and local authorities. The council said these incentives will be paid to BD only if the company meets specific investment and job creation commitments during the next eight years. The incentives include a Florida Qualified Target Industry tax refund and funding from the Miami-Dade County Targeted Jobs Incentive Fund.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.